Lenz T, Schulte K L, Wagner B, Lilienthal J, Gotzen R
Department of Medicine, Klinikum Steglitz-Free University, Berlin, Germany.
Eur Heart J. 1994 Jul;15(7):940-6. doi: 10.1093/oxfordjournals.eurheartj.a060614.
This 8-week, double-blind, multicentre study compared the efficacy and safety of the combination of quinapril and hydrochlorothiazide (HCTZ) with each drug as monotherapy. Outpatients with moderate to severe hypertension defined as supine diastolic blood pressure (DBP) > or = 105 mmHg and < or = 120 mmHg at the end of a 2 to 4-week placebo-baseline period were randomly assigned to one of the three treatments: once-daily 10 mg quinapril plus 12.5 mg HCTZ or monotherapy with these doses. After 4 weeks, the doses were to be doubled for the remaining 4 weeks. Three hundred and sixty-eight patients were randomized to double-blind medication; 346 completed the study. Seven patients withdrew due to lack of efficacy. Four patients withdrew due to side effects. In all three treatment groups, clinically significant reductions in DBP were achieved. Combination therapy was statistically more effective than each component taken as monotherapy. Adverse events were infrequent in all treatment groups. No patients experienced symptomatic hypotension or orthostatic hypotension.
这项为期8周的双盲多中心研究比较了喹那普利与氢氯噻嗪（HCTZ）联合用药及每种药物单独治疗的疗效和安全性。在为期2至4周的安慰剂基线期结束时，仰卧位舒张压（DBP）≥105 mmHg且≤120 mmHg的中重度高血压门诊患者被随机分配至三种治疗方案之一：每日一次10 mg喹那普利加12.5 mg HCTZ或这两种药物的单药治疗。4周后，在剩余4周内将剂量加倍。368例患者被随机分配接受双盲药物治疗；346例完成研究。7例患者因疗效不佳退出。4例患者因副作用退出。在所有三个治疗组中，DBP均实现了具有临床意义的降低。联合治疗在统计学上比每种药物单独治疗更有效。所有治疗组的不良事件均不常见。没有患者出现症状性低血压或体位性低血压。
